Gunderson Dettmer advised underwriters Cantor Fitzgerald & Co. in a proposed $75,000,000 “at-the-market” offering of shares of Arcus Biosciences, Inc. Public Offerings/Public Companies partners Jeffrey Vetter and Richard Blake and associate Colin Conklin led the team advising Cantor Fitzgerald.

Arcus, which trades on the New York Stock Exchange under the ticker symbol “RCUS,” is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities.